| Print
Merck & Co (MRK)
Common StockOpen
$120.76
Previous close
$119.75
Trade high
$122.66
Volume
13,083,323
Year high
$122.66
Year low
$73.31
Dividend yield
2.74%
Market capitalisation
$302.63 bn
P/E ratio
16.45
ISIN
US58933Y1055
This share can be held in a Dealing accountStocks and shares ISALifetime ISAJISASIPP
Share price
Dividends
| Previous | Latest | |
|---|---|---|
| Record date | 15/12/2025 | 16/03/2026 |
| Ex-dividend date | 15/12/2025 | 16/03/2026 |
| Payment date | 08/01/2026 | 07/04/2026 |
| Amount | $0.85 | $0.85 |
Company profile
Merck makes pharmaceutical products to treat several conditions in a number of therapeutic areas, including cardiometabolic disease, cancer, and infections. Within cancer, the firm's immuno-oncology platform, led by Keytruda, is a major contributor to overall sales. The company also has a substantial vaccine business aimed at preventing pediatric diseases, as well as Gardasil for human papillomavirus. Additionally, Merck sells animal health-related drugs. From a geographicalperspective, 47% of the company's sales are generated from US human health (pharmaceuticals and vaccines).
AJ Bell Management Limited (company number 03948391), AJ Bell Securities Limited (company number 02723420) and AJ Bell Asset Management Limited (company number 09742568) are authorised and regulated by the Financial Conduct Authority. All companies are registered in England and Wales at 4 Exchange Quay, Salford Quays, Manchester M5 3EE. See website for full details. AJ Bell procures the provision of the Morningstar Licensed Tools on an “as is” basis and does not guarantee the performance of or accept liability for the Licensed Tools. To the maximum extent permitted by law, AJ Bell excludes liability for the Licensed Tools, including liability for any failure, interruption, delay or defect in the performance of any Licensed Tool, unless it arises as a direct result of the negligence of AJ Bell.
© Copyright 2026 AJ Bell. All rights reserved.